Stahl-Hennig Christiane, Steinman Ralph M, Ten Haaft Peter, Uberla Klaus, Stolte Nicole, Saeland Sem, Tenner-Racz Klara, Racz Paul
German Primate Center, 37077 Göttingen, Germany.
J Virol. 2002 Jan;76(2):688-96. doi: 10.1128/jvi.76.2.688-696.2002.
Deletion of the nef gene from simian immunodeficiency virus (SIV) strain SIVmac239 yields a virus that undergoes attenuated growth in rhesus macaques and offers substantial protection against a subsequent challenge with some SIV wild-type viruses. We used a recently described model to identify sites in which the SIVDeltanef vaccine strain replicates and elicits immunity in vivo. A high dose of SIVDeltanef was applied to the palatine and lingual tonsils, where it replicated vigorously in this portal of entry at 7 days. Within 2 weeks, the virus had spread and was replicating actively in axillary lymph nodes, primarily in extrafollicular T-cell-rich regions but also in germinal centers. At this time, large numbers of perforin-positive cells, both CD8(+) T cells and CD3-negative presumptive natural killer cells, were found in the tonsil and axillary lymph nodes. The number of infected cells and perforin-positive cells then fell. When autopsy studies were carried out at 26 weeks, only 1 to 3 cells hybridized for viral RNA per section of lymphoid tissue. Nevertheless, infected cells were detected chronically in most lymphoid organs, where the titers of infectious virus could exceed by a log or more the titers in blood. Immunocytochemical labeling at the early active stages of infection showed that cells expressing SIVDeltanef RNA were CD4(+) T lymphocytes. A majority of infected cells were not in the active cell cycle, since 60 to 70% of the RNA-positive cells in tissue sections lacked the Ki-67 cell cycle antigen, and both Ki-67-positive and -negative cells had similar grain counts for viral RNA. Macrophages and dendritic cells, identified with a panel of monoclonal antibodies to these cells, were rarely infected. We conclude that the attenuated growth and protection observed with the SIVDeltanef vaccine strain does not require that the virus shift its characteristic site of replication, the CD4(+) T lymphocyte. In fact, this immunodeficiency virus can replicate actively in CD4(+) T cells prior to being contained by the host, at least in part by a strong killer cell response that is generated acutely in the infected lymph nodes.
从猿猴免疫缺陷病毒(SIV)毒株SIVmac239中删除nef基因,可产生一种病毒,该病毒在恒河猴体内生长减弱,并能为其提供针对后续某些SIV野生型病毒攻击的实质性保护。我们使用了一种最近描述的模型来确定SIVDeltanef疫苗株在体内复制并引发免疫的位点。将高剂量的SIVDeltanef接种到腭扁桃体和舌扁桃体,7天时它在这个进入门户中大量复制。在2周内,病毒扩散并在腋窝淋巴结中活跃复制,主要在富含滤泡外T细胞的区域,但也在生发中心。此时,在扁桃体和腋窝淋巴结中发现了大量穿孔素阳性细胞,包括CD8(+) T细胞和CD3阴性的推定自然杀伤细胞。然后感染细胞和穿孔素阳性细胞的数量下降。在26周时进行尸检研究时,每片淋巴组织中仅1至3个细胞与病毒RNA杂交。然而,在大多数淋巴器官中可长期检测到感染细胞,其中感染性病毒的滴度可能比血液中的滴度高出一个对数或更多。感染早期活跃阶段的免疫细胞化学标记显示,表达SIVDeltanef RNA的细胞是CD4(+) T淋巴细胞。大多数感染细胞不在活跃细胞周期中,因为组织切片中60%至70%的RNA阳性细胞缺乏Ki-67细胞周期抗原,并且Ki-67阳性和阴性细胞的病毒RNA颗粒计数相似。用一组针对这些细胞的单克隆抗体鉴定的巨噬细胞和树突状细胞很少被感染。我们得出结论,SIVDeltanef疫苗株观察到的生长减弱和保护作用并不要求病毒改变其特征性复制位点,即CD4(+) T淋巴细胞。事实上,这种免疫缺陷病毒在被宿主控制之前可以在CD4(+) T细胞中活跃复制,至少部分是通过在感染淋巴结中急性产生的强烈杀伤细胞反应来实现的。